financetom
Business
financetom
/
Business
/
Kezar to discontinue mid-stage trial for lupus treatment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kezar to discontinue mid-stage trial for lupus treatment
Oct 17, 2024 12:01 PM

Oct 17 (Reuters) - Kezar Life Sciences ( KZR ) said on

Thursday it would terminate its mid-stage trial studying its

experimental drug in patients with active lupus nephritis and

focus on the development of the drug in autoimmune hepatitis.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved